The agreement was facilitated by the Johnson & Johnson Innovation Centre in London. BenevolentAI has acquired a license to a select number of novel clinical stage drug candidates
ECHELON-2 is a global phase 3 randomized trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in patients with previously untreated CD30-positive mature T-cell
Both companies’ products target an abnormal form of the autologous cell surface-associated protein, Mucin 1 (MUC1), which is over-expressed in the majority of known tumor types. Due to
Additional small molecule compounds acting through the same target as LX9211 are also included in the exclusive arrangement. LX9211 is currently completing IND-enabling studies, with Phase 1 clinical
Acromegaly is a rare endocrine disorder in which the body produces excessive growth hormone, leading to abnormal growth throughout the body over time. The FDA's Orphan Drug Designation
Livatag (doxorubicine Transdrug, a nanoparticle formulation of doxorubicin) is currently being evaluated clinically as a monotherapy in a Phase III ReLive trial for second-line advanced hepatocellular carcinoma (HCC). More
PARP is a naturally-occurring enzyme in the body that repairs damage to DNA in cells. While this repair is a useful process to maintain the integrity of healthy
NeoGAA is a second-generation enzyme replacement therapy being studied for the treatment of Pompe disease. Pompe disease is a progressive, debilitating and often fatal neuromuscular disease caused by
In connection with the acquisition, EnBiotix has established EnBiotix. EnBiotix has also initiated a collaboration with Leipzig University and AMPT’s scientific co-founder, Professor Ralf Hoffmann, Ph.D. EnBiotix chairman
BCT-197 is currently in a Phase 2 study for the treatment of acute exacerbations of COPD (AECOPD). This study evaluated potential drug interactions between acumapimod and the antibiotic
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.